ARISTOCORT Drug Patent Profile

« Back to Dashboard

Which patents cover Aristocort, and what generic alternatives are available?

Aristocort is a drug marketed by Astellas and Fosun Pharma and is included in fourteen NDAs.

The generic ingredient in ARISTOCORT is triamcinolone. There are three drug master file entries for this compound. Additional details are available on the triamcinolone profile page.

Summary for ARISTOCORT

US Patents:	0
Applicants:	2
NDAs:	14
Raw Ingredient (Bulk) Api Vendors:	72
Clinical Trials:	2
DailyMed Link:	ARISTOCORT at DailyMed

Recent Clinical Trials for ARISTOCORT

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Innovaderm Research Inc.	Phase 4
Mayo Clinic	N/A
National Center for Research Resources (NCRR)	N/A

See all ARISTOCORT clinical trials

US Patents and Regulatory Information for ARISTOCORT

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Astellas	ARISTOCORT	triamcinolone acetonide	CREAM;TOPICAL	083017-003	Approved Prior to Jan 1, 1982		DISCN	No	No
Astellas	ARISTOCORT A	triamcinolone acetonide	CREAM;TOPICAL	083015-003	Approved Prior to Jan 1, 1982		DISCN	No	No
Astellas	ARISTOCORT	triamcinolone acetonide	OINTMENT;TOPICAL	080745-002	Approved Prior to Jan 1, 1982		DISCN	Yes	No
Fosun Pharma	ARISTOCORT	triamcinolone diacetate	INJECTABLE;INJECTION	011685-003	Approved Prior to Jan 1, 1982		DISCN	No	No
Astellas	ARISTOCORT	triamcinolone	TABLET;ORAL	011161-011	Approved Prior to Jan 1, 1982		DISCN	No	No
Astellas	ARISTOCORT A	triamcinolone acetonide	OINTMENT;TOPICAL	080750-003	Approved Prior to Jan 1, 1982		DISCN	No	No
Astellas	ARISTOCORT	triamcinolone diacetate	SYRUP;ORAL	011960-004	Approved Prior to Jan 1, 1982		DISCN	No	No

ARISTOCORT Market Dynamics, Financial Trajectory, Patent Status, and Generic Competition

Last updated: October 4, 2026

Aristocort is a legacy corticosteroid brand rather than a single globally standardized pharmaceutical product. In the United States, Aristocort-branded products have largely been displaced by generic triamcinolone formulations, including triamcinolone acetonide and triamcinolone diacetate products. The brand has limited current financial visibility, no identifiable blockbuster economics, and little evidence of meaningful remaining exclusivity in the U.S. market.

The commercial opportunity is concentrated in low-cost generic topical corticosteroids and, in certain markets, injectable formulations. Pricing is constrained by multiple manufacturers, pharmacy substitution, mature clinical use, and the absence of meaningful brand differentiation.

What is Aristocort and which active ingredients does it contain?

Aristocort has been used for products containing synthetic glucocorticoids, primarily triamcinolone derivatives. The exact active ingredient depends on the product and jurisdiction.

Aristocort product type	Active ingredient commonly associated with product	Typical dosage form	Primary use
Aristocort A	Triamcinolone acetonide	Cream, ointment, lotion, injectable suspension	Inflammatory dermatoses; selected joint or soft-tissue conditions
Aristocort	Triamcinolone diacetate or related triamcinolone formulation	Topical or injectable products, depending on market	Dermatologic and inflammatory conditions
Generic substitutes	Triamcinolone acetonide or triamcinolone diacetate	Cream, ointment, lotion, aerosol, injectable suspension	Same broad therapeutic categories

Product naming is inconsistent across countries. A market assessment must therefore distinguish the active ingredient, strength, route of administration, formulation, manufacturer, and regulatory jurisdiction. The U.S. FDA recognizes triamcinolone products through individual generic applications and product listings rather than through a single active Aristocort franchise [1,2].

What is the current FDA regulatory status of Aristocort?

The U.S. Aristocort franchise is a legacy product line with limited current brand presence. FDA databases list triamcinolone products by active ingredient and application, while commercial availability may vary by strength and dosage form.

Topical triamcinolone products are generally regulated as prescription drugs in the United States. The FDA-approved labeling covers indications such as corticosteroid-responsive dermatoses, with potency and dosing determined by concentration, vehicle, anatomical site, and duration of treatment [2].

Injectable triamcinolone products are separately regulated. Their labels address intra-articular, intramuscular, or other routes depending on the specific product. A topical Aristocort product cannot be treated as interchangeable with an injectable triamcinolone product merely because both use a triamcinolone derivative.

FDA status by product category

Category	U.S. regulatory position	Commercial implication
Topical triamcinolone acetonide	Approved generic products widely available	High substitution and low brand pricing power
Topical triamcinolone diacetate	Product-specific availability	Market depends on manufacturer and formulation
Injectable triamcinolone acetonide	Separate approved products	Institutional and specialty-channel competition
Aristocort-branded products	Limited or discontinued brand presence in the U.S.	Minimal direct branded revenue visibility

The FDA Orange Book does not function as a universal historical catalog of every Aristocort-branded product. It records approved products and patent or exclusivity information associated with listed applications. Product-level status must be checked by active ingredient, dosage form, strength, and application number [1].

When did Aristocort lose exclusivity?

Aristocort’s core market protection expired decades ago. Triamcinolone is an established corticosteroid active ingredient, and generic versions have been available for many years. The commercial issue is no longer loss of basic molecule exclusivity. It is competition among generic manufacturers and differences in formulation, supply reliability, and distribution.

No material U.S. market exclusivity appears to protect the historical Aristocort brand as a current commercial franchise. Any remaining protection would have to arise from a particular formulation, delivery system, manufacturing process, or product-specific patent rather than from triamcinolone itself.

Exclusivity profile

Protection category	Aristocort assessment
New chemical entity exclusivity	Expired
Core molecule patent	Expired or no longer commercially relevant
Brand-based exclusivity	No meaningful current U.S. protection identified
Formulation protection	Product-specific and generally old or narrow
Method-of-use protection	Limited commercial impact for mature corticosteroid indications
Orphan exclusivity	Not applicable to the standard Aristocort franchise
Pediatric exclusivity	No material current franchise-level effect identified

What patents protect Aristocort?

No current, commercially significant patent estate appears to protect Aristocort as a broad brand franchise in the United States. Historical patent rights associated with triamcinolone or older formulations would have expired long before the current generic market matured.

The relevant patent analysis is product-specific. Potential categories include:

• Vehicle composition patents for creams, ointments, lotions, or sprays.
• Suspension-stability patents for injectable products.
• Manufacturing-process patents.
• Container or delivery-device patents.
• Combination-product patents.
• Narrow method-of-use claims.

These rights do not normally prevent generic triamcinolone products from entering the market if the generic product uses a non-infringing formulation and satisfies FDA requirements.

Orange Book and Paragraph IV status

There is no apparent active Orange Book patent strategy supporting an Aristocort-branded U.S. franchise. A generic applicant challenging a currently listed patent would typically file a Paragraph IV certification under the Hatch-Waxman framework. For legacy Aristocort products, the practical importance of Paragraph IV litigation is low because the principal market has already shifted to generic triamcinolone products.

The absence of a current Aristocort patent dispute does not mean that every triamcinolone product is litigation-free. A newer vehicle, delivery system, or injectable formulation could carry separate patents unrelated to the historical brand.

How strong is the Aristocort patent estate?

The Aristocort patent estate is weak from a commercial perspective.

Patent-strength factor	Assessment
Core active ingredient	Very weak; mature generic compound
Brand-specific protection	Weak
Formulation differentiation	Potentially moderate for narrow products
Manufacturing barriers	Low to moderate, depending on sterile injectable form
Regulatory switching costs	Low for topical products
Litigation leverage	Low
Generic launch deterrence	Low

Topical triamcinolone products are relatively accessible to generic manufacturers. Injectable products present greater operational barriers because sterile manufacturing, suspension uniformity, particulate control, container closure, and supply-chain compliance require more specialized capabilities.

What formulations are protected by Aristocort-related intellectual property?

The main potential differentiation lies in the dosage form and vehicle rather than the active ingredient.

Topical formulations

Creams, ointments, lotions, and sprays can differ in:

• Drug concentration.
• Vehicle composition.
• Skin penetration.
• Occlusiveness.
• Cosmetic acceptability.
• Preservative system.
• Stability.
• Packaging.

Most of these differences are commercially relevant but do not create durable brand pricing power unless they support a clinically meaningful benefit or a differentiated regulatory claim.

Injectable formulations

Injectable triamcinolone products have more demanding technical requirements. Relevant quality attributes include:

• Particle-size distribution.
• Suspension uniformity.
• Sedimentation and resuspendability.
• Sterility assurance.
• Aggregation control.
• Syringe or vial compatibility.
• Shelf-life stability.

These factors can limit the number of capable suppliers, particularly for hospital or specialty channels. They do not, by themselves, establish a broad Aristocort patent moat.

What is the competitive landscape for Aristocort?

Aristocort competes primarily with generic triamcinolone products and other topical corticosteroids. The most direct substitutes include generic triamcinolone acetonide products, hydrocortisone, betamethasone, fluocinonide, fluocinolone, and desonide, depending on potency and indication.

Competitive group	Examples	Competitive basis
Direct generic substitutes	Triamcinolone acetonide cream, ointment, lotion	Same or closely related active ingredient
Lower-potency steroids	Hydrocortisone	Safety, OTC availability for selected strengths
Higher-potency steroids	Fluocinonide, betamethasone dipropionate	Greater potency for selected dermatoses
Alternative topical agents	Tacrolimus, pimecrolimus, crisaborole	Nonsteroidal positioning and chronic-use considerations
Injectable corticosteroids	Other triamcinolone and corticosteroid injections	Route, duration, physician preference, supply

Manufacturers in the generic topical market compete on contract pricing, wholesaler access, product availability, authorized-generic supply, and formulary placement. Physician loyalty to the Aristocort name is unlikely to offset generic substitution.

What is Aristocort’s financial trajectory?

Aristocort does not have a transparent, separately reported revenue stream in the public filings of major pharmaceutical companies. The brand’s financial trajectory is therefore best characterized qualitatively:

1. Initial branded growth occurred during the period when topical and injectable corticosteroids had fewer generic alternatives.
2. Revenue declined as triamcinolone products became broadly genericized.
3. Brand-level sales were eroded by pharmacy substitution and institutional purchasing.
4. Current economic value, where present, is more likely tied to generic product sales, licensing, distribution, or regional commercialization than to a protected Aristocort brand.

Revenue exposure

Revenue factor	Effect on Aristocort
Generic substitution	Strongly negative
Brand recognition	Limited financial impact
Pricing power	Low
Unit demand	Potentially stable because corticosteroid therapy remains common
Average selling price	Low and subject to tender pressure
Manufacturing complexity	More relevant for injectables
Regulatory exclusivity	Minimal
Commercial upside	Concentrated in supply reliability and niche formulations

No reliable public source establishes a current Aristocort-specific annual revenue figure. Reporting that assigns total triamcinolone-market sales to Aristocort would overstate the brand’s financial position.

What generic launch risks exist for Aristocort?

Generic entry risk is already realized for the core franchise. The relevant question is not whether generics can enter, but whether a manufacturer can maintain margins after entry.

Topical generic launch scenario

A new topical triamcinolone manufacturer would face:

• Low technical entry barriers.
• Multiple incumbent suppliers.
• Retail and wholesaler price competition.
• Limited brand loyalty.
• Potentially low gross margins.
• Working-capital pressure from inventory and chargebacks.

Injectable generic launch scenario

An injectable entrant would face higher barriers:

• Sterile manufacturing validation.
• FDA inspection and compliance requirements.
• Complex analytical testing.
• Hospital contracting.
• Supply continuity expectations.
• Potential shortage-related scrutiny.
• Greater exposure to manufacturing interruptions.

A successful injectable entrant may obtain better pricing than a topical entrant, but the market remains vulnerable to tenders, group purchasing organizations, and hospital substitution.

What patent litigation affects Aristocort?

No major current U.S. patent litigation appears to define the Aristocort market. Historical disputes involving triamcinolone products may have concerned generic approval, formulation claims, or manufacturing processes, but they do not appear to create a current branded Aristocort litigation barrier.

The litigation risk for a modern triamcinolone product would arise from:

• A formulation patent asserted against an ANDA applicant.
• A device or container patent.
• A process patent involving sterile manufacture.
• Trade-secret claims involving manufacturing know-how.
• False-advertising or labeling disputes.
• Product-liability claims unrelated to patent exclusivity.

For a mature topical corticosteroid, patent litigation is generally less important than FDA compliance, supply continuity, contracting, and pricing.

Are biosimilar risks relevant to Aristocort?

Biosimilar risk is not directly relevant. Aristocort contains a chemically synthesized corticosteroid rather than a biologic. The applicable competitive pathway is the generic-drug pathway, generally through an abbreviated new drug application, not the biosimilar pathway under the Public Health Service Act.

The economic effect is similar in one respect: substitution reduces branded pricing power. The regulatory mechanics are different.

How does Aristocort compare with newer dermatology drugs?

Factor	Aristocort/triamcinolone	Newer dermatology products
Molecule maturity	Long-established	Often protected or recently launched
Generic competition	Extensive	Limited during exclusivity
Price	Low	Frequently much higher
Differentiation	Primarily potency and vehicle	Mechanism, safety profile, delivery, or indication
Patent value	Low	Often central to commercial strategy
Prescriber behavior	Familiar, cost-driven	Driven by treatment response and tolerability
Reimbursement	Usually favorable	May require prior authorization

Aristocort remains commercially relevant where low cost, clinical familiarity, and broad availability matter. It is less competitive in markets seeking steroid-sparing treatment, chronic-use positioning, or differentiated safety profiles.

What is the geographic coverage of Aristocort?

Aristocort branding has appeared in multiple countries, but brand ownership, formulation, approval status, and commercial availability vary. A product sold under the Aristocort name outside the United States may not have the same active ingredient or dosage form as a historical U.S. product.

The strongest current commercial opportunity is likely in jurisdictions where:

• Brand prescribing persists.
• Generic substitution is less automatic.
• Local manufacturers control distribution.
• Injectable corticosteroids are purchased through institutional channels.
• Regulatory registration supports continued supply.

A global valuation should not aggregate Aristocort sales without separating country, formulation, active ingredient, and manufacturer.

What manufacturing and intellectual-property barriers remain?

Topical Aristocort-equivalent products have low-to-moderate manufacturing barriers. The principal risks are formulation consistency, microbial control, stability, packaging compatibility, and regulatory documentation.

Injectable products have higher barriers because sterile production and suspension performance require specialized equipment and validated processes. These barriers may support temporary supply advantages, but they are operational rather than brand-based.

The most durable commercial asset in this category is reliable manufacturing capacity. Patent ownership alone is unlikely to support premium pricing.

Key Takeaways

• Aristocort is a legacy triamcinolone brand with product definitions that vary by country and formulation.
• The core U.S. franchise has been displaced by generic triamcinolone products.
• No material current Aristocort brand exclusivity or broad patent moat is evident.
• Topical products face intense generic competition and low pricing power.
• Injectable triamcinolone products have higher manufacturing and regulatory barriers.
• Biosimilar competition is not applicable because triamcinolone is a chemically synthesized drug.
• Aristocort-specific revenue is not separately disclosed in major public-company reporting.
• Current commercial value depends on generic supply, formulation execution, distribution, and institutional contracting rather than patent exclusivity.
• Generic launch risk is already realized for topical products and remains primarily an execution risk for injectables.

FAQs

Is Aristocort still sold in the United States?

Historical Aristocort products have limited current branded visibility in the United States. Generic triamcinolone products provide the principal commercial supply.

Is Aristocort the same as triamcinolone?

Aristocort is a brand name associated with triamcinolone products, but the exact active ingredient may be triamcinolone acetonide, triamcinolone diacetate, or another product-specific formulation.

Can a generic manufacturer launch triamcinolone without an Aristocort license?

Generally, yes. A manufacturer can pursue its own FDA-approved generic product if it meets applicable requirements and does not infringe enforceable formulation, process, device, or other patents.

Does Aristocort have an active Orange Book patent?

No material current Orange Book patent estate appears to support Aristocort as a broad U.S. branded franchise. Product-level FDA records remain controlling for any particular formulation or application.

Is Aristocort commercially attractive for pharmaceutical licensing?

The standard topical franchise has limited licensing appeal because of low prices and generic competition. Injectable or technically differentiated formulations may offer greater value if they provide reliable supply, regulatory differentiation, or access to underserved geographic markets.

References

1. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

2. U.S. National Library of Medicine. (n.d.). DailyMed: Current medication information. https://dailymed.nlm.nih.gov/dailymed/

3. U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/

4. U.S. Food and Drug Administration. (n.d.). Abbreviated new drug application approvals. https://www.fda.gov/drugs/abbreviated-new-drug-application-anda/anda-approvals

5. U.S. Food and Drug Administration. (n.d.). Generic drugs: Questions and answers. https://www.fda.gov/drugs/questions-answers/generic-drugs-questions-answers